Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025

Centessa Pharmaceuticals plc

2025-Q2 EPS reported -$0.57 revenue$15,000,000

Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.
Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.
ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.
ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.
ORX489 in IND-enabling studies for neuropsychiatric disorders.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.